Hemangiomas of the liver are benign (non-cancerous) tumors that can cause a variety of medical problems, including pain, bleeding, and even liver failure. Surgery is often the only option for treating these tumors, but it can be complicated and risky. Fortunately, new research is exploring non-surgical treatment options for hemangiomas of the liver, offering hope to patients who may otherwise have no other choice.
A hemangioma is a benign tumor of the liver that is made up of a collection of blood vessels. It is typically found in children and is usually asymptomatic (without symptoms). However, in some cases, the tumor can cause symptoms such as abdominal pain, nausea, vomiting, or jaundice. In rare cases, a hemangioma can cause complications, such as bleeding, infection, or liver failure.
Hemangiomas of the liver are typically diagnosed through imaging tests such as ultrasound, CT scan, or MRI. Once a hemangioma is detected, the doctor may recommend a biopsy or other tests to confirm the diagnosis and assess the size and location of the tumor. Traditionally, the only treatment option for hemangiomas of the liver has been surgery. However, surgery can be risky and complicated, and it may not be an option for some patients. Fortunately, new research is exploring non-surgical treatment options for hemangiomas of the liver, offering hope to patients who may otherwise have no other choice.
There are several non-surgical treatment options available for hemangiomas of the liver. One of the most promising treatments is embolization, which involves injecting a substance into the blood vessels that feed the tumor, cutting off its blood supply and causing it to shrink. Embolization is less invasive than surgery and has fewer risks and side effects. Another non-surgical treatment option is cryoablation, which involves freezing the tumor with a probe. This treatment has been found to be effective in shrinking hemangiomas of the liver and can be done in an outpatient setting. In addition, there are several medications that can be used to treat hemangiomas of the liver. These include corticosteroids, which can reduce the size of the tumor, and interferon-alpha, which can help to shrink the tumor and reduce symptoms.
Non-surgical treatments for hemangiomas of the liver can have risks and side effects, just like any other medical procedure. Embolization, for example, can cause pain, infection, and nerve damage. Cryoablation can cause pain, swelling, and bleeding. Medications can cause side effects such as nausea, headaches, and fatigue. It is important to discuss all of the risks and side effects of any treatment option with your doctor before proceeding.
Hemangiomas of the liver can cause serious medical problems and traditionally, surgery has been the only treatment option. However, new research is exploring non-surgical treatment options, such as embolization, cryoablation, and medications, offering hope to patients who may otherwise have no other choice. While these treatments can be effective, they can also have risks and side effects, so it is important to discuss all of the options with your doctor before proceeding.
1.
Even when they are not paying attention, children are still learning.
2.
Survivors of high-risk neuroblastoma face substantial late effects of modern therapies
3.
Kate Middleton Reaches Cancer Treatment Milestone
4.
Pulled Myeloma Drug Improves Survival in Trial
5.
Genetics and Genetic Testing to Inform Myelofibrosis Clinical Management.
1.
Breast Cancer Secrets: AI-Powered Precision Medicine
2.
Revolutionizing Oncology Trials: Optimization, Matching, Diversity, and Decentralization
3.
Surprising Symptoms of Prostate Cancer: What You Need to Know
4.
Empowering Lung Cancer Diagnosis Through the Synergy of Advanced Technologies and Artificial Intelligence
5.
Artificial Intelligence in Oncology: Current Trends, Challenges and Future Outlook
1.
International Lung Cancer Congress®
2.
Future NRG Oncology Meeting
3.
Genito-Urinary Oncology Summit 2026
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part V
2.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part IV
3.
Pazopanib: A Game-Changer in Managing Advanced Renal Cell Carcinoma - Part IV
4.
Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update)
5.
Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Part III
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation